VIVORYON THERAPEUTICS (05Y.BE)
- GlobeNewswire
Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 Halle (Saale) / Munich, Germany, May 15, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its first quarter financial results for the period ended March
- GlobeNewswire
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 Halle (Saale) / Munich, Germany, May 08, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that its 2024 Annual General Meeting will be held on Friday, June 21, 2024 at 01:00 p.m. (CEST) at the A
- GlobeNewswire
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) doseStatistically significant improvement in k
